Effects of Intensive Early Physiotherapy Intervention After Myocardial Infarction on Quality of Life, Anxiety and Depression Scores: A Controlled Clinical Trial.

Physiother Res IntSep 6, 2026
Clinical ResearchCardiologyPhysical Medicine & RehabilitationOpen access

Kinga Balla, Karl K Haase, Alexander Wick

✦ AI-curated · Sources linked

In 30 seconds

This controlled clinical trial evaluated the effects of an intensive early physiotherapy program on health-related quality of life (HRQoL) and psychological well-being in 172 adults hospitalized after myocardial infarction. The intervention group demonstrated less deterioration in overall HRQoL and significant improvement in emotional well-being, with the Hospital Anxiety and Depression Scale (HADS-D) exceeding the minimal clinically important difference.

Key findings

  • The intervention group showed less deterioration in overall HRQoL (SRM: 0.04 vs. 0.1).
  • The MacNew emotional subscale improved more in the intervention group (SRM: 0.22 vs. 0.09).
  • HADS-D scores improved in the intervention group, exceeding the minimal clinically important difference of 1.7 points.

Why it matters

The findings suggest that structured early physiotherapy may enhance psychological outcomes and mitigate declines in quality of life for patients recovering from myocardial infarction, highlighting the importance of rehabilitation in acute care settings.

Source

PubMed · PMID 42541455Free full text on PubMed Central

Published in Physiother Res Int. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.